Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

SAN FRANCISCO -- Menopause hormone therapy (MHT) was tied to a weight-loss boost in postmenopausal women taking a weight loss ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

Key Takeaways Menopause hormone therapy appears to boost the effectiveness of tirzepatide (Zepbound)Women lost more weight ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

The two main GLP-1 medications that are approved by the U.S. Food and Drug Administration (FDA) are semaglutide and ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

SAN FRANCISCO -- In order to maximize weight loss, a GLP-1 receptor agonist may be needed both before and after bariatric ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

A weight loss drug has been found to dramatically reduce breast cancer tumour growth while still achieving significant weight ...